ArticleNature communications2015
Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies.
Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.The Journal of clinical investigation · 2020Trial
- Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.The Journal of infectious diseases · 2017Trial
- Linking biochemical and cellular efficacy of MERS coronavirus main protease inhibitors.ACS pharmacology & translational science · 2026Article
- Linking biochemical and cellular efficacy of MERS coronavirus main protease inhibitors.bioRxiv : the preprint server for biology · 2026Article
- HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice.Immunity · 2026Article
- Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies.The Journal of clinical investigation · 2025Article
- Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation.International journal of molecular sciences · 2025Review
- Assessing Tocolytic Potency: Variability and Accuracy of AUC Versus Amplitude-Based Assessment of Pregnant Human Myometrial Contractions Ex Vivo.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Neutralizing antibodies elicited in macaques recognize V3 residues on altered conformations of HIV-1 Env trimer.NPJ vaccines · 2024Article
- The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.JCI insight · 2024Article
- Emergent variant modeling of the serological repertoire to norovirus in young children.Cell reports. Medicine · 2023Article
- Tissue-resident memory T cells trigger rapid exudation and local antibody accumulation.Mucosal immunology · 2023Article
- A core epitope targeting antibody of SARS-CoV-2.Protein & cell · 2023Article
- Article
- Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission.Science advances · 2022Article
- Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19.bioRxiv : the preprint server for biology · 2021Article
- Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.Nature communications · 2021Article
- Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.medRxiv : the preprint server for health sciences · 2021Article
- Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection.Cell reports · 2021Article
- Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.Research square · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A new generation of HIV broadly neutralizing antibodies (bnAbs) with remarkable potency, breadth and epitope diversity has rejuvenated interest in immunotherapeutic strategies. Potencies defined by in vitro IC50 and IC80 values (50 and 80% inhibitory concentrations) figure prominently into the selection of clinical candidates; however, much higher therapeutic levels will be required to reduce multiple logs of virus and impede escape. Here we predict bnAb potency at therapeutic levels by analysing dose-response curve slopes, and show that slope is independent of IC50/IC80 and specifically relates to bnAb epitope class. With few exceptions, CD4-binding site and V3-glycan bnAbs exhibit slopes >1, indicative of higher expected therapeutic effectiveness, whereas V2-glycan, gp41 membrane-proximal external region (MPER) and gp120-gp41 bnAbs exhibit less favourable slopes <1. Our results indicate that slope is one major predictor of both potency and breadth for bnAbs at clinically relevant concentrations, and may better coordinate the relationship between bnAb epitope structure and therapeutic expectations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.